Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01365156 · ClinicalTrials.gov registry record · Phase 3
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase 3 study of Cervical Cancer and Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT01365156 is a Phase 3 study of Cervical Cancer and Adenocarcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01365156, a Phase 3 study of Cervical Cancer and Adenocarcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical research study is to learn if a surgical procedure called an extraperitoneal laparoscopic lymphadenectomy followed by chemotherapy and tailored radiation therapy can help to control the disease for a longer time than standard-of-care chemotherapy and whole pelvic radiation therapy.
Conditions Studied
Interventions
- RADIATION Chemoradiation
- PROCEDURE Extraperitoneal laparoscopic lymphadenectomy (EPLND)
Study Locations (3)
Texas
- Lyndon B. Johnson General Hospital - Houston
- University of Texas MD Anderson Cancer Center - Houston
Other
- Vall d'Hebron Hospital - Brussels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-08 |
| Est. Completion | 2020-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01365156
The ClinicalTrials.gov registry entry for NCT01365156 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chemoradiation is the first listed.
NCT01365156 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT01365156 about?
NCT01365156 is a clinical study titled "Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix". The goal of this clinical research study is to learn if a surgical procedure called an extraperitoneal laparoscopic lymphadenectomy followed by chemotherapy and tailored radiation therapy can help to control the disease for a longer time than standard-of-care chemotherapy and whole pelvic radiation ...
What is the current status of trial NCT01365156?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2011-08. Estimated completion is 2020-01-24.
What conditions does trial NCT01365156 study?
This clinical trial studies the following conditions: Cervical Cancer, Adenocarcinoma, Cervical Squamous Cell Carcinoma, Locally Advanced Malignant Neoplasm, Adenosquamous Carcinoma.
What interventions are being tested in trial NCT01365156?
The interventions under investigation include: Chemoradiation (RADIATION), Extraperitoneal laparoscopic lymphadenectomy (EPLND) (PROCEDURE).
Who is sponsoring clinical trial NCT01365156?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01365156 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RECRUITING · Phase 3
-
Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix
COMPLETED · Phase 3
-
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
COMPLETED · Phase 3
-
Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer
COMPLETED · Phase 3
-
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.